Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus

NCT ID: NCT02500979

Last Updated: 2018-11-02

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 34 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-08-17
• Study Completion Date: 2016-08-05

Brief Summary

This study is designed to investigate the clinical efficacy and safety of pramlintide co-administered as a fixed-dose ratio with basal-bolus SC insulin, delivered simultaneously via 2 separate pumps, in subjects with type 1 diabetes who are failing to achieve the desired level of glycemic control using insulin therapy.

Detailed Description

Potentially eligible subjects with Type 1 diabetes mellitus who are treated with with a basal-bolus insulin regimen through multiple daily injections or insulin pump at a total daily insulin dose ≤60 U, will be eligible. Visit 1 is approximately 3-6 weeks prior to randomization. Given some variability in HbA1c and C-peptide assays, re-testing for HbA1c and C-peptide can be performed within 18 days from the initial visit. Visit 2 is approximately 2-5 weeks prior to randomization. Subjects are on lispro insulin throughout study except during Visit 4 and Visit 5, the domicile 24 hr treatment period, when they are switched to regular insulin U-100.

Screen failed patients may be re-screened for inclusion in the study, as long as re-screening takes place at least 3 months after the original screening visit. If a subject is re-screened, he/she must continue to meet all inclusion/exclusion criteria. All study procedures of initial Visit 1 must be repeated at the re-screening visit.

Conditions

Type 1 Diabetes Mellitus

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

Pramlintide acetate & regular insulin

Pramlintide will be adiministered by sc infusion at a concentration of 1000ug/mL

Group Type: EXPERIMENTAL

Pramlintide acetate

Intervention Type: DRUG

Pramlintide acetate administered by a separate pump

Lispro insulin U-100

Intervention Type: DRUG

Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)

Regular insulin U-100

Intervention Type: DRUG

Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump

Placebo and regular insulin

Placebo is similar sterile solution without pramlintide.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Placebo administered by separate pump

Lispro insulin U-100

Intervention Type: DRUG

Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)

Regular insulin U-100

Intervention Type: DRUG

Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump

Interventions

Pramlintide acetate

Pramlintide acetate administered by a separate pump

Intervention Type: DRUG

Placebo

Placebo administered by separate pump

Intervention Type: DRUG

Lispro insulin U-100

Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)

Intervention Type: DRUG

Regular insulin U-100

Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump

Intervention Type: DRUG

Other Intervention Names

Pramlintide: SYMLIN; Humalog insulin lispro U-100; Humulin R; U-100

Eligibility Criteria

Inclusion Criteria

• Provision of informed consent prior to any study-specific procedures
• Female and/or male aged between 18 and 70 years
• Must have a prior diagnosis of T1DM
• Body mass index (BMI) <30 kg/m2
• Subjects are not on current treatment with pramlintide (Symlin) and have not received pramlintide during the 6-month period prior to enrollment
• Subjects should be willing to consume all of the components of the standardized meals administered during the study
• Negative serum pregnancy test for female subjects of childbearing potential
• Female subjects of childbearing potential must be 1 year postmenopausal, surgically sterile, or using an acceptable method of contraception for the duration of the study
• Male subjects must be surgically sterile or using an acceptable method of contraception for the duration of the study

Exclusion Criteria

• Recurrent severe hypoglycemia requiring assistance within 6 months before screening
• A history of hypoglycemia unawareness
• A confirmed diagnosis of gastroparesis
• Has been treated, is currently being treated, or is expected to require or undergo treatment with the following medications:
• Any oral antihyperglycemic agent or any other injectable antihyperglycemic agent that is not insulin
• Drugs that directly affect GI motility (eg, anticholinergic agents such as atropine)
• Drugs that slow the intestinal absorption of nutrients (eg, α-glucosidase inhibitors
• A history of gastric surgery (such as gastric banding, Roux- and Y bypass)
• Is expected to require or undergo treatment with acetaminophen after enrollment and at any point during the study
• Has experienced diabetic ketoacidosis within the last 24 weeks
• History of hospitalization within the last 6 months for glycemic control (for both hyperglycemia or hypoglycemia)
• Subject has any significant disease or disorder, which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, or may influence the results of the study, or the subject's ability to participate in the study
• Any clinically relevant abnormal findings, which, in the opinion of the investigator, may put the subject at risk because of his/her participation in the study.
• Pregnancy confirmed by a positive pregnancy test, or otherwise verified.
• Breast feeding
• Positive hepatitis C virus antibody (HCV Ab), hepatitis B virus surface antigen (HBsAg), hepatitis B virus core antibody (anti-Hbc), or human immunodeficiency virus 1/2 antibody (HIV-1/2 Ab) at Screening
• History of, or current alcohol or drug abuse
• Has donated blood within 2 months of Visit 1 (Screening) or is planning to donate blood during the study
• Has had a major surgery or a blood transfusion within 2 months before Visit 1 (screening)
• Participation in any clinical study with an investigational drug or new formulation of a marketed drug during the last 1 month prior to Visit 1

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Juvenile Diabetes Research Foundation

OTHER

Sponsor Role: collaborator

AstraZeneca

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Peter Ohman, MD

Role: STUDY_DIRECTOR

Medical Director AstraZeneca

Locations

Research Site

Chula Vista, California, United States

Research Site

Portland, Oregon, United States

Research Site

Chattanooga, Tennessee, United States

Countries

United States

References

Riddle MC, Nahra R, Han J, Castle J, Hanavan K, Hompesch M, Huffman D, Strange P, Ohman P. Control of Postprandial Hyperglycemia in Type 1 Diabetes by 24-Hour Fixed-Dose Coadministration of Pramlintide and Regular Human Insulin: A Randomized, Two-Way Crossover Study. Diabetes Care. 2018 Nov;41(11):2346-2352. doi: 10.2337/dc18-1091. Epub 2018 Sep 13.

Reference Type: DERIVED

PMID: 30213882 (View on PubMed)

Other Identifiers

D5570C00002

Identifier Type: -

Identifier Source: org_study_id